Literature DB >> 15132984

Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles.

Zoltán Nemes1, B Devreese, P M Steinert, J Van Beeumen, L Fésüs.   

Abstract

The accumulation of misfolded proteins in intracellular inclusions is a generic feature of neurodegenerative disorders. Although heavily ubiquitylated, the aggregated proteins are not degraded by the proteasomes. A possible reason for this phenomenon may be a modification of deposited proteins by transglutaminases forming gamma-glutamyl-epsilon-lysine (GGEL) cross-links between distinct proteins. Here, we show that the frequency of GGEL cross-links is an order of magnitude higher in Alzheimer's brain cortex than in age-matched or younger controls. This difference is due to the accumulation of GGEL cross-links in ubiquitin-immunopositive protein particles present in both Alzheimer's brains and those from aged individuals. The highly cross-linked protein aggregates show immunoreactivity to antibodies against tau and neurofilament proteins, and partially also to alpha-synuclein, indicating that these structures are inherent in Alzheimer's neurofibrillary tangles and Lewy bodies. Using mass sequence analysis, we identified the same six pairs of peptide sequences cross-linked in both senile and Alzheimer's specimens: Gln31 and Gln190 of HSP27 protein are cross-linked with Lys29 and Lys48 of ubiquitin and HSP27 therefore may cross-link two (poly)ubiquitin chains. One lysine residue of parkin and one of alpha-synuclein were also found to be cross-linked. The data suggest that cross-linking of (poly)ubiquitin moieties via HSP27 may have a role in the stabilization of the intraneuronal protein aggregates by interference with the proteasomal elimination of unfolded proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15132984     DOI: 10.1096/fj.04-1493fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  34 in total

Review 1.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

Review 2.  [Effector molecules of the innate immune system for treatment of wound infections].

Authors:  L Steinsträsser; S Langer; M Lehnhardt; H U Steinau
Journal:  Chirurg       Date:  2007-04       Impact factor: 0.955

3.  Screening for transglutaminase-catalyzed modifications by peptide mass finger printing using multipoint recalibration on recognized peaks for high mass accuracy.

Authors:  Cecilia Sundby Emanuelsson; Sandor Boros; Karin Hjernoe; Wilbert C Boelens; Peter Hojrup
Journal:  J Biomol Tech       Date:  2005-09

4.  Modification and reorganization of the cytoprotective cellular chaperone Hsp27 during herpes simplex virus type 1 infection.

Authors:  Shomita S Mathew; Megan P Della Selva; April D Burch
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

5.  Increased levels of gamma-glutamylamines in Huntington disease CSF.

Authors:  Thomas M Jeitner; Wayne R Matson; John E Folk; John P Blass; Arthur J L Cooper
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

6.  Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.

Authors:  Jonathan Wills; Jessica Jones; Thomas Haggerty; Valeriy Duka; Jeffrey N Joyce; Anita Sidhu
Journal:  Exp Neurol       Date:  2010-06-28       Impact factor: 5.330

Review 7.  Heat shock proteins: cellular and molecular mechanisms in the central nervous system.

Authors:  R Anne Stetler; Yu Gan; Wenting Zhang; Anthony K Liou; Yanqin Gao; Guodong Cao; Jun Chen
Journal:  Prog Neurobiol       Date:  2010-06-04       Impact factor: 11.685

8.  Phage display selection of efficient glutamine-donor substrate peptides for transglutaminase 2.

Authors:  Zsolt Keresztessy; Eva Csosz; Jolán Hársfalvi; Krisztián Csomós; Joe Gray; Robert N Lightowlers; Jeremy H Lakey; Zoltán Balajthy; László Fésüs
Journal:  Protein Sci       Date:  2006-11       Impact factor: 6.725

9.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

Review 10.  Chaperone signalling complexes in Alzheimer's disease.

Authors:  John Koren; Umesh K Jinwal; Daniel C Lee; Jeffrey R Jones; Cody L Shults; Amelia G Johnson; Laura J Anderson; Chad A Dickey
Journal:  J Cell Mol Med       Date:  2009-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.